Cargando…

Post-Marketing Surveillance of Levofloxacin 0.5% Ophthalmic Solution for External Ocular Infections

BACKGROUND: Levofloxacin 0.5% ophthalmic solution is an antibacterial formulation, which was approved and marketed for the treatment of ocular infections in Japan in 2000. OBJECTIVE: This study was designed to investigate the safety and efficacy of levofloxacin 0.5% ophthalmic solution in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanda, Yoshiko, Kayama, Tomoko, Okamoto, Shinji, Hashimoto, Masako, Ishida, Chiemi, Yanai, Tomoko, Fukumoto, Mitsuru, Kunihiro, Eiichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2012
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586049/ https://www.ncbi.nlm.nih.gov/pubmed/23075336 http://dx.doi.org/10.2165/11636020-000000000-00000

Ejemplares similares

Formulation and Evaluation of Levofloxacin and Betamethasone Ophthalmic Emulgel
por: Sabry, Hiba Sabah, et al.
Publicado: (2021)

Comparison of Drug Concentrations in Human Aqueous Humor after the Administration of 0.3% Gatifloxacin Ophthalmic Gel, 0.3% Gatifloxacin and 0.5% Levofloxacin Ophthalmic Solutions
por: Ding, Wenting, et al.
Publicado: (2015)

Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration
por: Sakai, Tatsuya, et al.
Publicado: (2019)

Prospective Observational Post-marketing Study of Tafluprost 0.0015%/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety
por: Takagi, Yasutaka, et al.
Publicado: (2016)

Development of Chitosan/Cyclodextrin Nanospheres for Levofloxacin Ocular Delivery
por: De Gaetano, Federica, et al.
Publicado: (2021)

Unorthodox ophthalmic preparations on the Ghanaian market: a potential risk for ocular and enteric infections
por: Kyei, Samuel, et al.
Publicado: (2020)

Levofloxacin-associated Encephalopathy with Severe Hyperventilation
por: Sugiura, Mieko, et al.
Publicado: (2019)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial
por: Goldberg, Ivan, et al.
Publicado: (2014)

Comparative study of the ocular efficacy and safety of diclofenac sodium (0.1%) ophthalmic solution with that of ketorolac tromethamine (0.5%) ophthalmic solution in patients with acute seasonal allergic conjunctivitis
por: Dehar, Navdeep, et al.
Publicado: (2012)

Difluprednate ophthalmic emulsion 0.05% (Durezol(®)) administered two times daily for managing ocular inflammation and pain following cataract surgery
por: Smith, Stephen, et al.
Publicado: (2010)

Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions
por: Deom, James E, et al.
Publicado: (2022)

An alternative in situ gel-formulation of levofloxacin eye drops for prolong ocular retention
por: Gupta, Himanshu, et al.
Publicado: (2015)

Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery
por: Bucci, Frank A, et al.
Publicado: (2016)

Covid-19, ocular manifestation and ophthalmic risks
por: Joob, B., et al.
Publicado: (2020)

Ocular Surface Changes Associated with Ophthalmic Surgery
por: Mikalauskiene, Lina, et al.
Publicado: (2021)

The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
por: Stonecipher, Karl G, et al.
Publicado: (2016)

Efficacy of 0.5% Levofloxacin and 5.0% Povidone-Iodine Eyedrops in Reducing Conjunctival Bacterial Flora: Metagenomic Analysis
por: Fan, Caixia, et al.
Publicado: (2020)

Ocular Manifestations in Hemodialysis Patients: Importance of Ophthalmic Examination in Prevention of Ocular Sequels
por: Kianersi, Farzan, et al.
Publicado: (2019)

Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%)
por: Marlowe, Zora T, et al.
Publicado: (2014)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
por: Rhee, Douglas J, et al.
Publicado: (2008)

Clinical and virological analysis of epidemic keratoconjunctivitis caused by adenovirus type 54 in a regional ophthalmic clinic in Kyushu, Japan
por: Uemura, Takashi, et al.
Publicado: (2018)

Safety of Fixed-Combination Bimatoprost 0.03%/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension
por: Sun, Xinghuai, et al.
Publicado: (2022)

Ophthalmic Myology: A Systematic Treatise on the Ocular Muscles
Publicado: (1902)

Ocular surface microbiota: Ophthalmic infectious disease and probiotics
por: Chiang, Ming-Cheng, et al.
Publicado: (2022)

Ophthalmic Myology: A Systematic Treatise on the Ocular Muscles
Publicado: (1904)

Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%
por: Stringer, William, et al.
Publicado: (2010)

Safety of intracameral injection of levofloxacin 0.5% eye drops single dose 0.6 ml preservative free on rabbit eye
por: Edwar, Lukman, et al.
Publicado: (2023)

Prophylactic ophthalmic bethametazone for sulfur mustard-induced ocular injury
por: Naderi, Mostafa, et al.
Publicado: (2009)

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
por: Lee, Daniel, et al.
Publicado: (2017)

Poor prognosis of elderly individuals >80 years of age with acute retinal necrosis
por: Yanai, Ryoji, et al.
Publicado: (2017)

Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use
por: Amon, Michael, et al.
Publicado: (2012)

A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
por: Khaimi, Mahmoud A
Publicado: (2018)

Conjunctival Microbiota in Patients With Type 2 Diabetes Mellitus and Influences of Perioperative Use of Topical Levofloxacin in Ocular Surgery
por: Zhu, Xiangjia, et al.
Publicado: (2021)

Development and validation of a simple UV spectrophotometric method for the determination of levofloxacin both in bulk and marketed dosage formulations
por: Maleque, Mahfuza, et al.
Publicado: (2012)

Levofloxacin-induced acute psychosis
por: Moorthy, Nagaraja, et al.
Publicado: (2008)

Acute Delirium Associated With Levofloxacin
por: Kogan, Yana, et al.
Publicado: (2018)

Levofloxacin-Induced Myoclonus and Encephalopathy
por: Reddy, V. Abhinay S. K., et al.
Publicado: (2020)

Levofloxacin-Induced Acute Pancreatitis
por: Neto Gonçalves, Tiago, et al.
Publicado: (2021)

Hepatotoxicity Secondary to Levofloxacin Use
por: Panahi, Ladan, et al.
Publicado: (2021)

Safety, efficacy, and patient acceptability of lidocaine hydrochloride ophthalmic gel as a topical ocular anesthetic for use in ophthalmic procedures
por: Page, Michael A, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ki0huk0d7uhm36jmnr4srl31uq